This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Teva Pharmaceutical Industries Limited. Active years: 2011-2013.
Company Filing History:
Years Active: 2011-2013
Title: The Innovative Journey of Shulamit Patashnik
Introduction
Shulamit Patashnik, an accomplished inventor residing in Reut, Israel, has made significant contributions to the field of pharmaceuticals. With two patents to her name, her innovative work showcases her commitment to developing effective medical treatments.
Latest Patents
Shulamit Patashnik's latest inventions focus on stable laquinimod preparations. The inventions relate to a pharmaceutical composition that includes a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier. These advancements hold promise for improved therapeutic applications and treatment options.
Career Highlights
Patashnik is currently a part of Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company. Her role there allows her to engage in groundbreaking research and development, driving forward the company’s mission to enhance patients' quality of life through innovative medications.
Collaborations
Throughout her career, Shulamit has collaborated with notable colleagues such as Daniella Licht and Adrian Gilbert. These partnerships reflect her ability to work effectively within a team while contributing unique insights and expertise to her projects.
Conclusion
Shulamit Patashnik's contributions to pharmaceutical innovations are notable, particularly in the realm of stable laquinimod preparations. Her work at Teva Pharmaceutical Industries Limited and collaboration with esteemed colleagues underline her position as a significant figure in the pharmaceutical industry. As she continues her innovative journey, the impact of her inventions is sure to enhance the landscape of medical treatments.